Coherus to Highlight Final P-II Study Data of Casdozokitug Regimen to Treat Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

Shots:

• Coherus will present the P-II trial data of casdozokitug (10mg/kg; IV; Q3W) + Tecentriq (1200mg) + Avastin (15mg/kg) vs PBO for 1L LA/M HCC patients (n=30), in both viral & non-viral diseases, at ASCO GI 2025
• Study (as of Sep 2024) met its 1EP of safety & all 2EPs depicting 38% ORR (5 CRs, 6 confirmed PRs), 8.1mos. mPFS & DCR of 58.6% (n=29) as per RECIST v1.1, while 43% ORR (5 CRs, 7 confirmed PRs), 8.4mos. mPFS & DCR of 60.7% (n=28) as per mRECIST
• Biomarker data showed IL-27 inhibition as well as NK & T-cells activation
  Coherus also initiated a new P-II trial (enrollment ongoing) assessing casdozo ± Loqtorzi & Avastin in LA/M HCC patients (n=~72) to find its safety, efficacy & dosing

Ref: Coherus | Image: Coherus

Related News:- Intas Pharmaceuticals to Acquire Coherus BioSciences’ Udenyca Business (Biosimilar, Neulasta)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com